M
Maribel Rodriguez-Torres
Researcher at San Juan Bautista School of Medicine
Publications - 138
Citations - 13678
Maribel Rodriguez-Torres is an academic researcher from San Juan Bautista School of Medicine. The author has contributed to research in topics: Ribavirin & Hepatitis C. The author has an hindex of 44, co-authored 137 publications receiving 13171 citations. Previous affiliations of Maribel Rodriguez-Torres include Consejo Nacional de Ciencia y Tecnología & Pontifical Catholic University of Puerto Rico.
Papers
More filters
Journal ArticleDOI
Treatment of HCV Infection by Targeting MicroRNA
Harry L.A. Janssen,Hendrik W. Reesink,Eric Lawitz,Stefan Zeuzem,Maribel Rodriguez-Torres,Keyur Patel,Adriaan J. van der Meer,Amy K. Patick,Alice Chen,Yi Zhou,Robert Persson,Barney D King,Sakari Kauppinen,Arthur A. Levin,Michael R. Hodges +14 more
TL;DR: The use of miravirsen in patients with chronic HCV genotype 1 infection showed prolonged dose-dependent reductions in HCV RNA levels without evidence of viral resistance.
Journal ArticleDOI
Sofosbuvir for previously untreated chronic hepatitis C infection
Eric Lawitz,Alessandra Mangia,David L. Wyles,Maribel Rodriguez-Torres,Tarek Hassanein,Stuart C. Gordon,Michael Schultz,M. Davis,Zeid Kayali,K. Rajender Reddy,Ira M. Jacobson,Kris V. Kowdley,L. Nyberg,G. Mani Subramanian,Robert H. Hyland,Sarah Arterburn,Deyuan Jiang,John McNally,Diana M. Brainard,William T. Symonds,John G. McHutchison,Aasim Sheikh,Zobair M. Younossi,Edward Gane +23 more
TL;DR: In a single-group study of sofosbuvir combined with peginterferon-ribavirin, patients with predominantly genotype 1 or 4 HCV infection had a rate of sustained virologic response of 90% at 12 weeks.
Journal ArticleDOI
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Francesca J. Torriani,Maribel Rodriguez-Torres,Jürgen K. Rockstroh,Eduardo Lissen,Juan González-García,Adriano Lazzarin,Giampiero Carosi,Joe Sasadeusz,Christine Katlama,Julio S. G. Montaner,Sette H,Sharon Passe,Jean De Pamphilis,Frank Duff,Uschi Marion Schrenk,Douglas T. Dieterich +15 more
TL;DR: Among patients infected with both HIV and HCV, the combination of peginterferon alfa-2a plus ribavirin was significantly more effective than either interferonalfa- 2a plus Ribavirin or pegin terferonAlfa-3a monotherapy.
Journal ArticleDOI
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
Mark S. Sulkowski,David F. Gardiner,Maribel Rodriguez-Torres,K. Rajender Reddy,Tarek Hassanein,Ira M. Jacobson,Eric Lawitz,Anna S. Lok,Federico Hinestrosa,Paul J. Thuluvath,Howard J. Schwartz,David R. Nelson,Gregory T. Everson,Timothy Eley,Megan Wind-Rotolo,Shu-Pang Huang,Min Gao,Dennis Hernandez,Fiona McPhee,Diane Sherman,R. Hindes,William T. Symonds,Claudio Pasquinelli,Dennis M. Grasela +23 more
TL;DR: Once-daily oral daclatasvir plus sofosbuvir was associated with high rates of sustained virologic response among patients infected with HCV genotype 1, 2, or 3, including patients with no response to prior therapy with telaprevir or boceprevir.
Journal ArticleDOI
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
Ira M. Jacobson,Stuart C. Gordon,Kris V. Kowdley,Eric M. Yoshida,Maribel Rodriguez-Torres,Mark S. Sulkowski,Mitchell L. Shiffman,Eric Lawitz,Gregory T. Everson,Michael J. Bennett,Eugene R. Schiff,M. Tarek Al-Assi,G. Mani Subramanian,Di An,Ming Lin,John McNally,Diana M. Brainard,William T. Symonds,John G. McHutchison,Keyur Patel,Jordan J. Feld,Stephen Pianko,David R. Nelson +22 more
TL;DR: In patients with HCV genotype 2 or 3 infection for whom treatment with peginterferon and ribavirin was not an option, 12 or 16 weeks of treatment with sofosbuvir and ribvirin was effective.